Fig. 8: Laser-induced CNV model in NHPs are used to evaluate the efficacy of nAMD by AAVv128-anti-VEGF vector.
From: An adeno-associated virus variant enabling efficient ocular-directed gene delivery across species
a The anti-VEGF protein levels of monkey treated with suprachoroidal injection of AAV8-anti-VEGF vector and AAVv128-anti-VEGF vector (1×1012 vg/eye, 100 μL volume, n = 1) were measured at Day 56. AAV8-anti-VEGF vector and AAVv128-anti-VEGF vector were injected into suprachoroidal space at Day0, six laser spots were applied around the macula of each eye using laser at 28-days. The NHPs were sacrificed at Day 56 (after induction of choroidal neovascularization by Laser-induced CNV model) and eyes were harvested. The retinal tissues of the NHP retinas after suprachoroidal injection were isolated and the anti-VEGF protein expression level of AAV8-treated group and AAVv128-treated group were measured by ELISA. b Timeline of studying AAV-anti-VEGF vector to evaluate the efficacy of nAMD by using Laser-induced CNV model in NHP eyes. c, d Fluorescein fundus angiograph (FFA) was used to determine the number of Grade IV lesions. Representative FFA of NHP eyes treated with suprachoroidal injection of Vehicle, AAV8-anti-VEGF vector and AAVv128-anti VEGF vector at 35-days (c) and 49-days (d) (2×1012 vg/eye, 100 μL volume, n = 8). e Percentage of Grade IV lesions with suprachoroidal injection of Vehicle (formulation buffer), AAV8-anti-VEGF vector and AAVv128-anti-VEGF vector. Numbers on the top of bars show the number of Grade IV lesions scored over the total number of assessable lesions (six laser spots/eye, n = 8). OD oculus dextrus, OS oculus sinister, FFA fundus fluorescence angiography. Values represent mean ± SD. P values were determined by one-way ANOVA. Compared with vehicle, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Compared with AAV8, #P < 0.05, ##P < 0.01 (P = 0.0074). n = 8/group. Source data are provided as a Source Data file.
